Eikon Therapeutics, Inc.

Filing Date

Feb 6, 2026

Transaction Date

Feb 4, 2026

Accession Number

0001193125-26-041544

Form Type

4

Net Trading Amount

$5.0M

Footnotes

1. (F1)These shares are held by Lux Co-Invest Opportunities II, L.P. ("LCIO II"). Lux Co-Invest Partners II, LLC ("LCIP II") is the general partner of LCIO II and exercises voting and dispositive power over the shares noted herein held by LCIO II. Peter Hebert and Josh Wolfe, a member of the Issuer's board of directors (the "Individual Lux Managers"), are the individual managing members of LCIP II. The Individual Lux Managers, and as the sole managers of LCIP II, may be deemed to beneficially own the shares held by LCIO II. Each of LCIP II and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein.
2. (F2)These shares are held by Lux Total Opportunities, L.P. ("LTO"). Lux Total Opportunities Partners, LLC ("LTOP") is the general partner of LTO and exercises voting and dispositive power over the shares noted herein held by LTO. The Individual Lux Managers are the individual managing members of LTOP. The Individual Lux Managers, as the sole managers of LTOP, may be deemed to beneficially own the shares held by LTO. Each of LTOP and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein.
3. (F3)The Series A Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date.
4. (F4)The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.
5. (F5)These shares are held by Lux Ventures V, L.P. ("LVV"). Lux Venture Partners V, LLC ("LVPV") is the general partner of LVV and exercises voting and dispositive power over the shares noted herein held by LVV. The Individual Lux Managers are the individual managing members of LVPV. The Individual Lux Managers, as the sole managers of LVPV, may be deemed to beneficially own the shares held by LVV. Each of LVPV and the Individual Lux Managers disclaims beneficial ownership over these shares except to the extent of their pecuniary interest therein.
6. (F6)The Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.
7. (F7)The Series B-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.
8. (F8)The Series C Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.
9. (F9)The Series C-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.
10. (F10)The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.